Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...
Nasdaq

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in ...
Business Insider

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous ...

HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria ...
MPR

FDA Expands Dupixent Approval to Children Aged 2 to 11 With CSU

The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.

Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU

Sanofi ( SNY) and Regeneron’s ( REGN) Dupixent was approved in the U.S. as the first biologic medicine for young children ...
Seeking Alpha

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability ...
Nasdaq

Celldex Reports Promising Phase 2 Results for Barzolvolimab in Chronic Spontaneous Urticaria, Showing Sustained Clinical Benefits Seven Months Post-Treatment

41% of patients treated with barzolvolimab 150 mg Q4W continue to experience a complete response up to 76 weeks after the completion of dosing, indicating long-term efficacy. 48% of patients report ...